marijuana stock news

Growblox Sciences, Inc. (GBLX)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue –   –   –   –  
Cost of Revenue – – – –
Gross Profit –   –   –   –  
Operating Expenses
Research Development – – – –
Selling General and Administrative 678 1,780 1,495 131
Non Recurring – – – –
Others – – – –
Total Operating Expenses – – – –
Operating Income or Loss (678) (1,780) (1,495) (131)
Income from Continuing Operations
Total Other Income/Expenses Net (0) 0 0 (559)
Earnings Before Interest And Taxes (678) (1,780) (1,495) (132)
Interest Expense – – – 14
Income Before Tax (678) (1,780) (1,495) (146)
Income Tax Expense – – – –
Minority Interest 56 110 50 –
Net Income From Continuing Ops (622) (1,670) (1,445) (705)
Non-recurring Events
Discontinued Operations – – – –
Extraordinary Items – – – –
Effect Of Accounting Changes – – – –
Other Items – – – –
Net Income (622) (1,670) (1,445) (705)
Preferred Stock And Other Adjustments – – – –
Net Income Applicable To Common Shares (622) (1,670) (1,445) (705)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Organigram Holdings Inc. (OGRMF) harvests years of innovation and research, launches The Edison Project

Organigram harvests years of innovation and research, launches The Edison Project We…

Organigram Holdings Inc. (OGRMF) Releases Unprecedented Virtual Reality Tour of Moncton Campus

Organigram Releases Unprecedented Virtual Reality Tour of Moncton Campus, Home of Edison…

Reliq Health Technologies Inc. (RQHTF) Announces Quarterly Reporting Call

Reliq Health Technologies Announces Quarterly Reporting Call and Plans to Restate Financials…

AbbVie (ABBV) to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology Annual Meeting

AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021…